PerProtocol

Site 1

Site 2


Treatment adherence^{a}

AL (N = 176)

AQAS (N = 176)

Difference in means

95% CI

pvalue

AL (N = 173)

AQAS (N = 181)

Difference in means

95% CI

pvalue


Mean % of treatment (SD)^{b}

99.8% (2.5)

98.6% (7.9)

1.17

− 0.09, 2.42

0.068

97.0% (12.8)

99.2% (6.3)

− 2.19

− 4.37, 0.00

0.050

Correct treatment^{c}

AL (N = 179)

AQAS (N = 174)

Odds Ratio

95% CI

pvalue

AL (N = 178)

AQAS (N = 176)

Odds ratio

95% CI

pvalue


Correct dose^{d}

163 (93.1%)

144 (83.7%)

2.64

1.30, 5.39

0.008

128 (77.6%)

149 (88.7%)

0.44

0.24, 0.81

0.008

Correct timing^{e}

163 (93.1%)

166 (96.5%)

0.49

0.18, 1.34

0.165

136 (82.4%)

163 (97.0%)

0.14

0.05, 0.38

< 0.001

Correct duration^{f}

172 (98.3%)

170 (98.8%)

0.67

0.11, 4.09

0.668

156 (95.6%)

164 (97.6%)

0.42

0.13, 1.40

0.159

Correct treatment^{g}

154 (88.0%)

140 (81.4%)

1.68

0.92, 3.04

0.089

125 (75.8%)

148 (88.1%)

0.42

0.23, 0.76

0.004

Intentiontotreat

Site 1

Site 2


Treatment adherence^{a}

AL (N = 175)

AQAS (N = 172)

Difference in means

95% CI

pvalue

AL (N = 165)

AQAS (N = 168)

Difference in means

95% CI

pvalue


Mean % of treatment (SD)^{b}

99.8% (2.5)

98.7% (7.9)

1.14

− 0.09, 2.36

0.069

97.0% (12.7)

99.1% (6.0)

− 2.30

− 4.40, − 0.19

0.032

Correct treatment^{c}

AL
(N = 175)

AQAS (N = 172)

Odds Ratio

95% CI

pvalue

AL
(N = 165)

AQAS (N = 168)

Odds
Ratio

95% CI

pvalue


Correct dose^{d}

166 (92.7%)

146 (83.9%)

2.45

1.22, 4.90

0.011

138 (77.5%)

155 (88.1%)

0.47

0.26, 0.83

0.010

Correct timing^{e}

166 (92.7%)

168 (96.6%)

0.45

0.17, 1.23

0.120

149 (83.7%)

170 (96.6%)

0.18

0.07, 0.45

< 0.001

Correct duration^{f}

179 (97.8%)

174 (98.9%)

0.51

0.09, 2.81

0.439

169 (94.9%)

171 (97.2%)

0.55

0.18, 1.67

0.291

Correct treatment^{g}

156 (87.2%)

142 (81.6%)

1.53

0.85, 2.74

0.153

135 (75.8%)

154 (87.5%)

0.45

0.26, 0.79

0.005

 ^{a}Proportion of all tablets received − information on the number of tablets taken is missing from one participant in the AL group at Site 1 (n = 174). Measure of Effect = Difference of means; AQAS is the reference group
 ^{b}Percent of treatment = total number of tablets taken by the patient/total number of tablets prescribed
 ^{c}Odds Ratios were calculated using logistic regression, with ORs calculated using AQAS as the reference group
 ^{d}Dose is defined as the number of tablets prescribed by weight or age. For AQAS: 1 tablet per day for three days. For AL: 5 to < 15 kg = 1 tablet twice a day for 3 days, 15 to < 25 kg = 2 tablets twice a day for three days
 ^{e}Timing is defined as the number of times per day the treatment should be taken. For AQAS: once daily. For AL: two times per day
 ^{f}Duration is defined as the number of days the treatment should be taken. For both AQAS and AL: 3 days
 ^{g}Correct treatment = correct dose + correct timing + correct duration, in which the criteria for all three factors (as above) are met